Addressing the challenges of CRS in bispecific monoclonal antibody cancer therapy

Immuno-Oncology Insights 2022; 3(6), 315–318

DOI: 10.18609/ioi.2022.031

Published: 15 June 2022
Commentary
Anjali Vaze, Peter Kuebler

The benefit/risk ratio of immuno-oncology (I–O) agents is crucial when considering treatment options for cancer patients. Highly potent and targeted oncology agents come with high hopes of patient benefit. The tradeoff that comes with greater potency is the potential for serious and life-threatening toxicity, such as cytokine release syndrome (CRS). It is incumbent upon physicians, drug developers, and all other stakeholders to ensure a benefit/risk profile for these drugs that optimizes the patient experience throughout their treatment journey, iterating on mitigation measures that work while continuing to explore interventions that might further reduce risk of CRS.